Open AccessChoroidal neovascularization secondary to Sorsby fundus dystrophy treated with systemic bevacizumab (Avastin ® )
Author(s) -
Prager Franz,
Michels Stephan,
Geitzenauer Wolfgang,
SchmidtErfurth Ursula
Publication year - 2007
Publication title -
acta ophthalmologica scandinavica
Language(s) - English
Resource type - Journals
eISSN - 1600-0420
pISSN - 1395-3907
DOI - 10.1111/j.1600-0420.2007.00927.x
Subject(s) - medicine , bevacizumab , choroidal neovascularization , ophthalmology , visual acuity , fluorescein angiography , fundus (uterus) , fundus fluorescein angiography , surgery , chemotherapy
. Purpose: A case of choroidal neovascularization (CNV) secondary to Sorsby fundus dystrophy (SFD) treated with systemic bevacizumab (Avastin ® ) Methods: A 41‐year‐old woman presented with CNV secondary to SFD in her better eye. The patient received three initial infusions of bevacizumab at a dose of 5 mg/kg at 2 week intervals and one additional infusion because of CNV recurrence at the 7 month follow‐up. Results: At 16 month follow‐up, visual acuity had improved from 20/50 at baseline to 20/25; optical coherence tomography and fluorescein angiography showed no evidence of CNV activity. Conclusion: Systemic bevacizumab seems to be a promising treatment option for CNV secondary to SFD.